Two Promising Skin Cancer Drugs
Two promising skin cancer drugs are generating a lot of excitement in the healthcare community. The two experimental drugs, pembrolizumab and nivolumab, work by blocking the pathway cancers use to disguise themselves from the immune system.
In a trial of 411 patients with advanced melanoma, the medication, pembrolizumab, helped 69% of the patients survive for at least a year. The survival rate among those with advanced melanoma that has spread to other organs, is usually only six months.
The other drug, nivolumab, was tested in combination with an immunotherapy drug, ipilimumab, and 85% of patients survived for over a year, and 79% survived for over two years. More….
Category: News
